Amendment Number No. 1 to the Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Oncology Limited, dated May 2, 2024

Amendment Number No. 1

to Drug Discovery Collaboration and License Agreement

THIS AMENDMENT NO. 1 (the “Amendment”), is made and entered into as of the date of the last signature below (the “Effective Date”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation with a business address of 780 Brannan Street, San Francisco, CA 94103 (hereinafter “Olema”) and Aurigene Oncology Limited (earlier known as Aurigene Discovery Technologies Limited), a corporation organized under the laws of India, having its principal place of business at 39-40(P), KIADB Industrial Area, Electronics City Phase II, Hosur Road, Bangalore-560100, India (hereinafter “Aurigene”). Olema and Aurigene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, under the terms of the Drug Discovery Collaboration and License Agreement (the “Agreement”), dated June 7, 2022, by and between the Parties, the Parties desired to pursue a collaborative research program more particularly described in the Agreement; and

WHEREAS, the Parties hereto wish to amend the Agreement and they desire to memorialize such changes in this Amendment No. 1;

NOW, THEREFORE, in consideration of the following mutual promises, covenants and conditions hereinafter set forth, the Parties hereto agree as follows:

If to Olema: Olema Pharmaceuticals, Inc.

780 Brannan Street

San Francisco, CA 94103

Attention: Legal Department

Phone: [ * ]

Email: [ * ]

If to Aurigene: Aurigene Oncology Limited

39-40(P), KIADB Industrial Area,

Electronics City Phase 2, Hosur Road

Bangalore - 560100 Karnataka India

Attn: Chief Executive Officer

Email: [ * ]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Effective Date.
 

OLEMA PHARMACEUTICALS, INC. AURIGENE ONCOLOGY LIMITED